

EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS

Yoshihisa Shitara,¹ Hitoshi Sato,¹ and Yuichi Sugiyama²

¹*School of Pharmaceutical Sciences, Showa University, Shinagawa-ku, Tokyo 142-8555, Japan; email: shitara@pharm.showa-u.ac.jp, sato hito@pharm.showa-u.ac.jp*

²*Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan; email: sugiyama@mol.f.u-tokyo.ac.jp*

Key Words transporter, pharmacokinetics, quantitative prediction of drug-drug interaction

■ **Abstract** Recent studies have revealed the import role played by transporters in the renal and hepatobiliary excretion of many drugs. These transporters exhibit a broad substrate specificity with a degree of overlap, suggesting the possibility of transporter-mediated drug-drug interactions with other substrates. This review is an overview of the roles of transporters and the possibility of transporter-mediated drug-drug interactions. Among the large number of transporters, we compare the K_i values of inhibitors for organic anion transporting polypeptides (OATPs) and organic anion transporters (OATs) and their therapeutic unbound concentrations. Among them, cephalosporins and probenecid have the potential to produce clinically relevant OAT-mediated drug-drug interactions, whereas cyclosporin A and rifampicin may trigger OATP-mediated ones. These drugs have been reported to cause drug-drug interactions in vivo with OATs or OATP substrates, suggesting the possibility of transporter-mediated drug-drug interactions. To avoid adverse consequences of such transporter-mediated drug-drug interactions, we need to be more aware of the role played by drug transporters as well as those caused by drug metabolizing enzymes.

INTRODUCTION

The kidney and the liver play important roles in the elimination of drugs and xenobiotics from the body (1–5). Cumulative in vivo and in vitro studies have revealed the importance of transporters in the renal and hepatobiliary excretion of many drugs and other xenobiotics (1–5). Recent studies to investigate the molecular mechanism of renal and hepatobiliary excretion have revealed that multiple transporters are expressed in the kidney and liver in animals and humans, as well as revealing their function, tissue distribution, and intracellular localization (6–15). These transporters exhibit broad substrate specificity with a degree of overlap.

As each transporter accepts multiple drugs and/or xenobiotics as its substrates, it may be competitively inhibited by other coadministered drugs and/or xenobiotics, which may lead to drug-drug interactions involving the transporter (15, 16). In this review, we summarize quantitatively the probability of drug-drug interactions from *in vitro* and *in vivo* studies.

THE MECHANISM OF RENAL AND HEPATOBILIARY EXCRETION OF DRUGS

The Mechanism of Renal Excretion—The Role of Transporters

In the kidney, drugs are excreted in the urine as the net result of glomerular filtration, tubular secretion, and reabsorption (4) (Figure 1). The mechanism of glomerular filtration is simply ultrafiltration of drugs and xenobiotics, which do not bind to macromolecules such as plasma proteins, and, therefore, transporters are not involved in this process. Therefore, for drugs eliminated only by filtration, renal excretion is not saturable and cannot be inhibited by other drugs. On the other hand, in the case of tubular secretion, several active secretion mechanisms have been reported in the proximal tubules, which are mainly mediated by transporters.




Figure 1 Mechanism of drug elimination in the kidney. Drug elimination in the kidney takes place by glomerular filtration and secretion at the proximal tubules. However, they may return to the systemic circulation via a process of drug reabsorption. Transporters are involved in drug secretion and reabsorption.

Hence, this process is saturable and may be inhibited by coadministered drugs. As with tubular secretion, the reabsorption process is sometimes mediated by transporters in the proximal tubules. Therefore, the reabsorption process may be, in part, saturable and inhibited by coadministered drugs. Renal clearance can be, in general, described by the following equation:

$$\begin{aligned} \text{CL}_R &= (1 - \text{FR}) \cdot (f_u \cdot \text{GFR} + \text{CL}_{\text{sec}}) \\ &= (1 - \text{FR}) \cdot \left(f_u \cdot \text{GFR} + \frac{Q_R \cdot f_u \cdot \text{CL}_{R,\text{int}}}{Q_R + f_u \cdot \text{CL}_{R,\text{int}}} \right), \end{aligned} \quad 1.$$

where f_u , GFR, FR, CL_{sec} , Q_R , and $\text{CL}_{R,\text{int}}$ represent protein unbound fraction in the blood, glomerular filtration rate [ml min^{-1}], the fraction reabsorbed, renal secretion clearance, renal blood flow rate, and intrinsic clearance of tubular secretion, respectively (4). FR and $\text{CL}_{R,\text{int}}$ are partly saturable and can be inhibited, suggesting the possibility of drug-drug interactions.

The Mechanism of Hepatobiliary Excretion—The Role of Transporters

In the liver, drugs are first taken up into hepatocytes, followed by metabolism including oxidation (mediated by cytochrome P450, Phase I) and conjugation (mediated by conjugation enzymes, Phase II), and excreted into the bile (Phase III) (3) (Figure 2). Some drugs are excreted as intact drugs without metabolism. In addition, drugs excreted in the intact form may pass into the blood again by enterohepatic circulation. Drugs or their metabolites, once taken up into the liver, may undergo secretion into the blood across the sinusoidal membrane, followed by the hepatobiliary or renal excretion. To date, transporters have been shown to play a role in hepatic uptake, biliary excretion, and the secretion into the blood across the sinusoidal membrane (Figure 2). Hepatic clearance can be described by the following equation (17, 18):

$$\text{CL}_H = \frac{Q_H \cdot f_u \cdot \text{CL}_{H,\text{int,all}}}{Q_H + f_u \cdot \text{CL}_{H,\text{int,all}}}, \quad 2.$$

where CL_H , Q_H , and $\text{CL}_{H,\text{int,all}}$ represent the hepatic clearance; hepatic blood flow; and overall intrinsic clearance of biliary excretion, including uptake, metabolism, and biliary excretion, respectively. $\text{CL}_{H,\text{int,all}}$ can be described by the following equation (3, 19):

$$\text{CL}_{H,\text{int,all}} = \text{PS}_{\text{influx}} \times \frac{\text{CL}_{H,\text{int}}}{\text{PS}_{\text{efflux}} + \text{CL}_{H,\text{int}}}, \quad 3.$$

where $\text{PS}_{\text{influx}}$ and $\text{PS}_{\text{efflux}}$ are the membrane permeability across the sinusoidal membrane from the outside to the inside and from the inside to the outside of cells, respectively, and $\text{CL}_{H,\text{int}}$ represents the exact intrinsic clearance for the metabolism and/or biliary excretion of the unbound drugs. When $\text{CL}_{H,\text{int}}$ is negligibly low




Figure 2 Mechanism of drug elimination in the liver. Drugs are taken up into hepatocytes via transporters and/or passive diffusion, followed by metabolism and/or biliary excretion. Drugs are possibly effluxed into the circulation via sinusoidal membrane.

compared with PS_{efflux} ($CL_{H,\text{int}} \ll PS_{\text{efflux}}$), Equation 3 gives

$$CL_{H,\text{int,all}} = PS_{\text{influx}} \times \frac{CL_{H,\text{int}}}{PS_{\text{efflux}}}. \quad 4.$$

If PS_{efflux} is much lower than $CL_{H,\text{int}}$ ($CL_{H,\text{int}} \gg PS_{\text{efflux}}$), Equation 3 gives

$$CL_{H,\text{int,all}} = PS_{\text{influx}}. \quad 5.$$

It should be noted that the uptake of drugs via the sinusoidal membrane (PS_{influx}), which is partly mediated by transporters, is a determinant of the net hepatic clearance regardless of the other processes, i.e., $CL_{H,\text{int}}$ and PS_{efflux} . Therefore, hepatic clearance may be affected when the uptake clearance of drugs is altered, even if the drug finally undergoes metabolism. On the other hand, the excretion of drugs via the bile canicular membrane, which is partly mediated by transporters, is a determinant of the net hepatic clearance, unless PS_{efflux} is negligibly low compared with $CL_{H,\text{int}}$. Therefore, except in this case, the change in the biliary excretion may affect the net hepatic clearance. If PS_{efflux} is much lower than $CL_{H,\text{int}}$, only a drastic reduction in the biliary excretion will affect the net hepatic clearance, possibly leading to a transporter-mediated drug-drug interaction.

TRANSPORTERS IN THE KIDNEY AND LIVER

Recently, many types of transporters have been isolated in the kidney and liver from animals and humans. Their substrate specificity has been characterized using cRNA-injected oocytes and/or cDNA transfected cells. Generally, amphipathic organic anions with relatively high molecular weights are eliminated from the liver by metabolism and/or biliary excretion, whereas small and hydrophilic organic anions are excreted into urine (7). In this section, the characteristics of transporters expressed in the kidney and liver and their functions are summarized.

Transporters in the Kidney

Figure 3 shows transporters expressed in the kidney of rats and humans. Some transporters are located on the basolateral membrane (blood side), whereas others are located on the brush border membrane (luminal side), and these transporters contribute to membrane transport, resulting in tubular secretion and/or reabsorption. In this section, the molecular aspects of renal transporters are summarized.




Figure 3 Transporters in the kidney. Transporters expressed in human and rodent kidney are summarized in this figure. Some of the transporters in rodents are expressed only in either rats or mice.

ORGANIC ANION TRANSPORTERS The transport of organic anions is mainly mediated by organic anion transporters (OATs). Rat Oat1 has been isolated as a renal transporter that is involved in the renal uptake of organic anions like p-aminohippuric acid (PAH) in an exchange of dicarboxylates (20). OAT1–5 have been identified as human OAT family transporters (21–24). Among them, OAT1–4 are expressed in the human kidney and OAT2 and 5 are expressed in the liver (21–24). In the kidney, OAT1–3 are localized on the basolateral membrane, whereas OAT4 is localized on the brush border membrane (24). Each of these transporters in the OAT family has a similar substrate specificity. These transporters accept organic anions with a relatively small molecular weight with some exceptions. They accept PAH, methotrexate (MTX), nonsteroidal antiinflammatory drugs, and antiviral nucleoside analogues as substrates (25–27). They also accept more lipophilic organic anions, such as estrone 3-sulfate and ochratoxin A, and even an organic cation, cimetidine (24, 25, 28).

P-GLYCOPROTEIN P-glycoprotein (P-gp) consists of two subclasses: MDR1 (MDR1 in humans, Mdr1a and 1b in rats and mice) and MDR2 [MDR2 (or 3) in humans and Mdr2 in rats and mice] (8). The former is the well-known multidrug resistance transporter, whereas the latter is a translocator for phospholipids (8). In the kidney, P-gp is localized on the brush border membrane and acts as an efflux transporter into the urine (8). P-gp is also expressed in the liver (8). In the liver, it is localized on the bile canalicular membrane (8). P-gp was originally found as an overexpressing transporter in tumor tissues, and it acts as a multidrug resistance protein, although it has also been identified in normal tissues such as kidney, liver, blood-brain barrier, and intestine (8). P-gp substrates include anticancer drugs (such as vincristine, vinblastine, doxorubicin, daunorubicin, etoposide, and paclitaxel), immunosuppressants (such as cyclosporin A), verapamil, digoxin, and steroids (such as aldosterone and cortisole) (29–36).

PEPTIDE TRANSPORTERS In the kidney, two isoforms of peptide transporters have been identified: PEPT1 and PEPT2 (37). PEPT1 and 2 are localized on the brush border membrane of the proximal tubule (38, 39). PEPT1 is expressed in the early part of the proximal tubule (pars convoluta), whereas PEPT2 is expressed further along the proximal tubule (pars recta) (38, 39). PEPT1 and 2 accept not only di- or tri-peptides but also several therapeutic drugs. PEPT1 accepts therapeutic drugs such as β -lactam antibiotics (such as cephalexin, cefibuten, cephadrine), ACE inhibitors (enalapril and temocapril), and valacyclovir (37, 40, 41). Although there are few therapeutic drugs that have been reported to be substrates of PEPT2 (cephalexin), there are many drugs that interact with PEPT2 as inhibitors (37).

ORGANIC CATION TRANSPORTERS OCT1 and OCT2 are expressed in the kidney, whereas only OCT1 is expressed in the liver (14, 42). OCT2 is highly expressed in the kidney (14, 42). In human kidney, these transporters are localized in the basolateral membrane and are important organic cation transporters for renal

tubular secretion (14, 42). These are pH-independent, electrogenic, and polyspecific transporters (14, 42). These transporters accept organic cations with relatively low molecular weight (type I cations), such as tetraethylammonium (TEA), as substrates (42, 43). Cimetidine, choline, dopamine, acyclovir, and zidovudine are also reported to be substrates (44–46).

OCTN OCTN1 is strongly expressed in the kidney but not in the adult liver (47). In OCTN1-expressing HEK293 cells, pH-sensitive uptake of TEA has been observed (47). An inward proton concentration gradient stimulated the efflux of TEA in OCTN1-expressing *Xenopus laevis* oocytes, indicating that OCTN1-mediated transport couples with proton antiport (48). OCTN1 is considered to be localized on the brush border membrane of the kidney. Substrates include quinidine and adriamycin as well as TEA (47, 48). OCTN2, an isoform of OCTN1, was isolated from human placenta and it was also found to be expressed in the kidney (49, 50). Although OCTN2 accepts TEA as its substrate, the transporter activity is not as high as that of OCTN1. OCTN2 can also accept carnitine, a zwitterion that is a cofactor essential for β -oxidation of fatty acids, and several mutations in mRNA encoding OCTN2 result in systemic carnitine deficiency owing to the poor renal reabsorption of carnitine (51). This fact suggests that OCTN2 plays a role in the renal reabsorption of carnitine. This transporter also accepts cephaloridine and other cationic compounds, such as verapamil, quinidine, and phyrilamine, in addition to TEA and carnitine, although it is not yet known whether this transporter takes part in the renal reabsorption and/or excretion of these compounds together with OCTN1 (52, 53).

Transporters in the Liver

Figure 4 shows transporters in the liver. In the liver, uptake transporters are located on the sinusoidal membrane (blood side) and efflux transporters are found on the bile canalicular membrane, although some efflux transporters are on the sinusoidal membrane and take part in the secretion into the blood.

ORGANIC ANION TRANSPORTING POLYPEPTIDES In the liver, the uptake of many organic anions is mediated by organic anion transporting polypeptides (OATPs), although OAT2 and 5 are also reported to be expressed in the liver. In humans, OATP-A, B, C, D, E, F, and 8 have been identified, and OATP-B, C, and 8 are expressed in the liver (54–58). In rats, the OATP family is also conserved and Oatp1, 2, and 4 are expressed in the liver (59–61). These transporters are localized on the sinusoidal membrane of the liver. OATPs mainly accept bulky and amphipathic organic anions as substrates, although they also accept neutral compounds such as digoxin. The substrates of OATP family transporters include therapeutic drugs such as HMG-CoA reductase inhibitors, ACE inhibitors [enalapril and temocaprilat (an active form of temocapril)], and digoxin (55, 56, 58, 62–65). Many other therapeutic drugs also interact with OATP family transporters as inhibitors,




Figure 4 Transporters in the liver. Transporters expressed in human and rodent liver are summarized in this figure. Some of the transporters in rodents are expressed only in either rats or mice.

suggesting there may be other drugs that are taken up into the liver via OATP family transporters.

MULTIDRUG RESISTANCE ASSOCIATED PROTEINS In TR⁻ and Eisai hyperbilirubinemic rats (EHBRs), which exhibit hyperbilirubinemia owing to a deficiency in the biliary excretion of bilirubin glucuronide, mutations in the transporter, multidrug resistance-associated protein 2 (Mrp2), have been found (66, 67). This finding and the comparison of the biliary excretion of several compounds between normal rats and Mrp2-deficient rats suggests that it plays an important role in the biliary excretion of multispecific organic anions, including glucuronide conjugates [bilirubin glucuronide, E3040 glucuronide, estradiol 17 β -D-glucuronide (E₂17 β G), grepafloxacin glucuronide, SN-38 glucuronide, glycyrrhizin, etc.], glutathione conjugate [glutathione bimane (GSB), dinitrophenyl glutathione (DNP-SG), leucotrienes (LTC₄, D₄ and E₄), etc.], grepafloxacin, MTX, pravastatin, SN-38, and temocaprilat (8, 68–72). This transporter is localized in the bile canalicular membrane of the liver (73–75). Its human counterpart (MRP2) has been isolated from the cisplatin-resistant tumor cells, KCP4 (76). This transporter is

also localized on the bile canalicular membrane of the liver and accepts multiple organic anions, including glucuronides (bilirubin monoglucuronide, bilirubin bisglucuronide, E3040 glucuronide, E₂17 β G, grepafloxacin glucuronide, LTC₄, etc.), glutathione conjugates (DNP-SG, GSB, glutathione-methylfluorescein, etc.), pravastatin, MTX, vinblastine, vincristine, etoposide, etc. (33, 77–88).

Human MRP3 is also a MRP family transporter, which is expressed in the liver. However, this transporter is localized on the sinusoidal membrane and considered to be involved in secretion into the blood. It also accepts many glucuronides, glutathione conjugates, MTX, etc. (89, 90).

BREAST CANCER RESISTANT PROTEIN Breast cancer resistant protein (BCRP) has been cloned from human MCF-7 breast cancer cells as a multidrug resistance transporter (91–93). This transporter also belongs to the ABC transporter family (91–93). However, its structure differs from that of other ABC transporters, such as MDR1 and MRP, which contain two tandem repeats of transmembrane and ABC domains. BCRP consists of only one ABC and one transmembrane domain, and, therefore, it is referred to as a half-sized ABC transporter (91–93). This transporter is also expressed in normal tissues including the liver (94). In the liver, it is located on the bile canalicular membrane (94). Many sulfated conjugates, such as estrone 3-sulfate (E₁S), dehydroepiandrosterone sulfate, 4-methylumbelliferone sulfate, etc., are transported by BCRP (95). MTX, estradiol 17 β -D-glucuronide, and 2,4-dinitrophenyl-S-glutathione are also transported but to a lesser extent compared with E₁S (95). BCRP preferentially transports sulfate conjugates (95).

METHODS FOR EVALUATING TRANSPORTER-MEDIATED DRUG-DRUG INTERACTIONS IN THE KIDNEY AND THE LIVER

In Vitro Transport Systems Using Tissues, Cells, Membrane Vesicles, and Transporter-Expressing Systems

In vitro studies using tissues, cells, and membrane vesicles prepared from animals have made it easy to characterize the mechanism of drug transport and estimate the elimination rates of drugs via liver or kidney. Recently, these systems prepared from human sources have also become available, and they are likely to be of great help in the drug discovery and other related research areas. Transporter cDNA-transfected cells or cRNA-injected oocytes are also available for drug transport studies. Because of the scarcity of human tissue sources, transporter-expressing systems will be useful for predicting transporter-mediated drug-drug interactions.

KIDNEY SLICES Kidney slices were used for the study to evaluate the renal uptake of compounds/drugs from the basolateral side (96–99). In rat kidney slices, the

uptake of compounds via Oct2, Oat1, Oat3, and a novel peptide transporter has been observed (96–99). The uptake of compounds into kidney slices is much lower than the renal intrinsic uptake clearance *in vivo*, which may be partly due to diffusion from the surface of the slices. Although extrapolation of the renal clearance using kidney slices has not been reported, it may be used as a tool for the prediction of transporter-mediated drug-drug interactions in the kidney. At the time of writing, there have been no reports using human kidney slices; however, the use of this tool will be useful for the prediction of transporter-mediated drug-drug interactions in the kidney.

ISOLATED AND CULTURED HEPATOCYTES Isolated and cultured hepatocytes have been used as an *in vitro* model of the liver (100, 101). The hepatic uptake of peptidic endothelin antagonists using isolated rat hepatocytes showed that their *in vitro* uptake clearance could be extrapolated to give their *in vivo* uptake clearance, assuming a well-stirred model (100). Thus, isolated hepatocytes are a good tool for the evaluation of drug uptake in the liver and transporter-mediated drug-drug interactions in the liver. Recently, because of the progress in the techniques of cryopreservation, it seems possible to preserve frozen human hepatocytes in such a way that most of their enzymatic activity is retained (102). They have been used to examine drug metabolism interactions, including induction of metabolic enzymes (103–105). Recently, we have examined the uptake of taurocholate (TC) and estradiol-17 β -D-glucuronide in freshly isolated and cryopreserved human hepatocytes (106). This study suggested that their active transports were retained even in cryopreserved human hepatocytes, although the activity was decreased after cryopreservation in some lots of hepatocytes (106). Therefore, cryopreserved human hepatocytes, at least, retain transporter function and they can be used as a useful experimental system for examining the mechanism of the hepatic uptake of drugs and interactions with other drugs (106).

LIVER SLICES Liver slices are also used for the study of drug uptake in the liver (107, 108). Olinga et al. examined the uptake of digoxin, a substrate of human OATP8 [OATP1B3] and rat Oatp2 [Oatp1a4], and temperature-dependent uptake was observed (107). Liver slices are supplemented with nonparenchymal cells, and, therefore, the interaction between hepatocytes and other cells and the effect of other cells on the function of hepatocytes can also be examined.

MEMBRANE VESICLES Today, membrane vesicles prepared from the brush border and basolateral membrane in the kidney and from the sinusoidal and bile canalicular membrane in the liver are readily available for the study of renal and hepatobiliary transport (109–114). The advantages of using this system for transport studies are (a) drug transport across the basolateral (sinusoidal) and apical (brush border or bile canalicular) membrane can be measured separately, (b) intracellular binding and/or metabolism can be ignored, and (c) buffers inside and outside vesicles can be changed easily. On the other hand, using this system has limitations because it

requires a driving force for transport, so it is impossible to use this system without prior characterization.

STUDIES USING GENE EXPRESSION SYSTEMS Using transporter expression systems, the kinetic parameters for the target transporter can be obtained. Once the responsible transporter for the drugs in question has been identified, the possibility of drug-drug interactions can be examined using the gene expression system, i.e., without hepatocytes, membrane vesicles, and tissue slices. As human tissue samples are scarcely distributed, transporter-expressing systems greatly help drug transport studies. With the information of contributions of specific transporter(s) to the total uptake of drugs in human liver or kidney, quantitative prediction of drug uptake in human tissues is possible. The method to estimate the contributions of specific transporters is described below. cDNA-transfected cells and cRNA-injected oocytes can be used as gene expression systems. More recently, cultured cells stably transfected with both uptake and efflux transporters have become available (85, 115). OATP-C/OATP2 [OATP1B1] and MRP2 transfected cells and OATP8 [OATP1B3] and MRP2 transfected cells have been reported (Figure 5) (85, 115). Using them, hepatobiliary transport can be measured as vectorial transcellular transport when these cells are cultured on a porous membrane. This will make it easy to predict transporter-mediated drug-drug interactions in the liver.

ESTIMATION OF THE CONTRIBUTION OF A SPECIFIC TRANSPORTER The estimation of the contribution of specific transporter(s) is important for the quantitative prediction of the uptake in human tissues, including liver and kidney from the *in vitro* data using transporter-expressing systems, and even for the quantitative




Figure 5 Experimental system for the estimation of transcellular transport of drugs mediated by OATP-C/OATP2 [OATP1B1] and MRP2. OATP-C/OATP2 [OATP1B1] and MRP2 double-transfected MDCK cells are seeded in a membrane insert. The basal-to-apical flux of drugs across the MDCK cell monolayer was examined to estimate the transcellular transport mediated by OATP-C/OATP2 [OATP1B1] and MRP2.

prediction of transporter-mediated drug-drug interaction. Here, we show the method to estimate it in *in vitro* assays.

First, injection of cRNA coding a transporter results in its expression on the plasma membrane of *Xenopus laevis* oocytes that have been used for expression cloning, functional analysis, or transport assays (117, 118). However, hybridization of mRNA with antisense oligonucleotide coding a specific sequence for the target transporter specifically reduces the expression of the transporter (117, 118). Comparison of the transporter activity in cRNA-injected oocytes in the presence and absence of antisense nucleotides gives the contribution of each transporter to the net transport (117, 118).

Kouzuki et al. have proposed a method using reference compounds (119, 120). They measured the uptake of reference and test compounds at the same time in transporter cDNA-transfected COS7 cells and rat hepatocytes and calculated the contribution using the following equation (119, 120):

$$\text{Contribution} = \frac{CL_{\text{hep,ref}}/CL_{\text{COS,ref}}}{CL_{\text{hep,test}}/CL_{\text{COS,test}}}, \quad 6.$$

where CL_{hep} and CL_{COS} represent the uptake clearance of compounds into hepatocytes and transporter cDNA transfected cells, respectively. $CL_{\text{hep,ref}}$ and $CL_{\text{hep,test}}$ represent the uptake clearance of the reference and test compounds, respectively. The reference compounds should be specific substrates, otherwise the contribution will be overestimated (119, 120). More recently, Hirano et al. proposed a method to estimate the contributions of human transporters (OATP-C/OATP2 [OATP1B1] and OATP8 [OATP1B3]) to the total hepatic uptake using estrone 3-sulfate and cholecystokinin octapeptide (CCK8) as specific substrates, respectively, and actually estimated their contributions to the hepatic uptake of pitavastatin (121). They also estimated their contributions by uptake in human hepatocytes and transporter expression systems normalized by their transporter expression levels measured by Western blot analysis (121). The contributions of OATP-C/OATP2 [OATP1B1] and OATP8 [OATP1B3] estimated by these two different methods were comparable, suggesting the validity of this method (121).

A specific inhibitor of a transporter also helps to estimate its contribution to the total uptake. To identify a specific inhibitor, we examined the comparative inhibitory effects of many compounds on rat Oatp1 [Oatp1a1] and Oatp2 [Oatp1a4] (122). Among them, we found that digoxin specifically inhibited Oatp2 [Oatp1a4] with no effect on Oatp1 [Oatp1a1] (122). We also found several compounds which preferentially inhibited one of these transporters (122). These inhibitors may be used to estimate the contributions of Oatp1 [Oatp1a1] and Oatp2 [Oatp1a4] at appropriate concentrations (122). However, the selectivity of most of the preferential inhibitors in this report was not very high, and inhibitors that act as selective inhibitors over a wider range of concentrations are needed (122).

EVALUATION OF TRANSPORTER-MEDIATED DRUG-DRUG INTERACTIONS

In this section, the inhibitory effects of therapeutic drugs and the possibility of clinically relevant drug-drug interactions based on transporter-mediated processes are described.

How to Evaluate the Extent of Transporter-Mediated Drug-Drug Interactions

Previously, our group has suggested how to predict the extent of drug-drug interactions based on drug metabolism using *in vitro* studies (123, 124). This method can also be applied to transporter-mediated drug-drug interactions (125). As transporter-mediated influx or efflux follows the Michaelis-Menten equation, the clearance can be described as follows:

$$CL = \frac{V_{\max}}{K_m + S_u} + P_{\text{dif}}, \quad 7.$$

where CL is the influx or efflux clearance; V_{\max} , K_m , and P_{dif} are the maximum transport rate, Michaelis constant, and nonsaturable transport clearance, respectively; and S_u is the protein-unbound substrate concentration. In the presence of competitive inhibitors, it can be described as follows:

$$CL (+\text{inhibitor}) = \frac{V_{\max}}{K_m \cdot (1 + I_u/K_i) + S_u} + P_{\text{dif}}, \quad 8.$$

where I_u is the protein-unbound inhibitor concentration and K_i is the inhibition constant. It should be noted that the I_u value is the protein-unbound inhibitor concentration outside the cells for influx transporters, whereas it is that inside the cells for efflux transporters. On the other hand, in the case of noncompetitive inhibition, it can be described as follows:

$$CL (+\text{inhibitor}) = \frac{V_{\max}/(1 + I_u/K_i)}{K_m + S_u} + P_{\text{dif}}. \quad 9.$$

When the protein unbound substrate concentration is negligibly low compared with the K_m value, the influx or efflux clearance via transporters can be described by the following equation, both for competitive and noncompetitive inhibition:

$$CL (+\text{inhibitor}) = \frac{V_{\max}}{K_m \cdot (1 + I_u/K_i)} + P_{\text{dif}}. \quad 10.$$

Therefore, transporter-mediated influx or efflux clearance (i.e., net influx or efflux clearance subtracted by the nonsaturable clearance) is decreased by the following equation:

$$\frac{CL_{\text{transporter}}(+\text{inhibitor})}{CL_{\text{transporter}}(\text{control})} = \frac{1}{1 + I_u/K_i} = R, \quad 11.$$

where $CL_{\text{transporter}}$ represents transporter-mediated influx or efflux clearance.

When a transporter, which is a key determinant of the disposition of a drug, is inhibited by a concomitantly administered drug, the area under the blood/plasma concentration (AUC) after an oral administration will increase by at most $\frac{1}{R}$ -fold when the drug is predominantly excreted in the liver. In such cases, hepatic or renal intrinsic clearances decrease by R -fold and, therefore, this R value is one of the indicators of the severity of a drug-drug interaction. It should be particularly useful for the evaluation of in vivo drug-drug interactions to avoid false negative predictions.

For the liver transporters, the estimation of I_u should account for the inhibitors in the portal vein as well as the hepatic artery when the inhibitor drug is orally administered. In this case, I_u is not equal to the inhibitor concentration in the circulating blood. Ito et al. have suggested a method to estimate the inhibitor concentration at the inlet to the liver using the following equation (Figure 6) (123, 124):

$$I_u = f_u \cdot (I_{\text{sys}} + I_{\text{pv}}) = f_u \cdot \left(I_{\text{sys}} + \frac{V_{\text{abs}}}{Q_H} \right), \quad 12.$$




Figure 6 A model for estimating the inhibitor concentration at the liver after oral administration. I_{inlet} is the inhibitor concentration at the inlet to the liver. It can be estimated from the inhibitor concentration in the hepatic artery (I_a) plus that in the portal vein (I_{pv}).

where I_{sys} and I_{pv} are the inhibitor concentration in the circulating blood and portal vein, respectively; f_u is the blood protein unbound fraction; v_{abs} is the absorption rate from the intestine to the portal vein; and Q_H is the hepatic blood flow. When the intestinal absorption is described by a first-order rate constant, this equation becomes (123, 124)

$$I_u = f_u \cdot \left(I_{\text{sys}} + \frac{F \cdot D \cdot k_a \cdot e^{-k_a \cdot t}}{Q_H} \right) \leq f_u \cdot \left(I_{\text{sys}} + \frac{F \cdot D \cdot k_a}{Q_H} \right), \quad 13.$$

where F is the fraction absorbed from the gastrointestinal tract, D is the dose, and k_a is the absorption rate constant. To avoid a false negative prediction, the unbound inhibitor concentration should be estimated by $f_u \cdot (I_{\text{sys}} + \frac{F \cdot D \cdot k_a}{Q_H})$ for a drug-drug interaction based on a hepatic transporter-mediated process.

To date, there are many published inhibition studies of renal and hepatic uptake transporters: OATs and OATPs. In this section, the inhibitory effects of therapeutic drugs on these transporters are evaluated using K_i values, comparing them with the therapeutic concentrations.

OAT-Mediated Drug-Drug Interactions

In the kidney, the OAT family transporters are involved in the uptake of organic anions with relatively low molecular weights into the renal tubules, although OAT2 and 5 are localized in the liver and OAT4 is expressed in the brush border membrane of the kidney and may be involved in efflux from the renal tubules into the urine (21–24). These OAT family transporters are inhibited by several compounds, including therapeutic drugs (Supplemental Table 1, Follow the Supplemental Material link from the Annual Reviews home page at <http://www.annualreviews.org>). Supplemental Table 1 gives a partial list of therapeutic drugs that interact with OAT family transporters, together with their maximum plasma concentration and maximum plasma unbound concentration in a clinical situation and R value.

The calculated R values suggest that many inhibitor drugs of OAT family transporters do not cause a serious drug-drug interaction because of the relatively low plasma concentrations compared with their K_i values (Supplemental Table 1). However, some cephalosporin antibiotics and probenecid exhibited low R values and, therefore, may lead to clinically relevant drug-drug interactions (Supplemental Table 1). These results suggest that the concomitant use of these drugs with OAT substrate drugs, which are mainly excreted in the urine, should be very carefully monitored. Such use may cause at least a partial reduction in the intrinsic clearance for renal secretion, possibly leading to an increase in plasma concentration.

OATP-Mediated Drug-Drug Interactions

Among OATP family transporters, OATP-B [OATP2B1], OATP-C/OATP2 [OATP1B1], and OATP8 [OATP1B3] are expressed in the human liver and are involved in the hepatic uptake of several compounds, including therapeutic drugs (54–58). Although, in rats, some Oatp family transporters, such as Oatp1 [Oatp1a1],

Oat-k1 [Oatp1a3], and k2, are reported to be expressed in the kidney (126–130), their human counterparts have not been characterized. As shown in Supplemental Table 2 (Follow the Supplemental Material link from the Annual Reviews home page at <http://www.annualreviews.org>), several therapeutic drugs are reported to inhibit OATP family transporters. Because they are hepatic uptake transporters, R values were calculated based on not only the maximum inhibitor unbound therapeutic concentration in the circulating blood but also that in the inlet to the liver, calculated by Equation 13 (123, 124). Values calculated based on the unbound concentration in the inlet to the liver are given as R'. Inhibitors of OATP family transporters consist of bulky compounds, including anions, neutral compounds, and even cations (Supplemental Table 2). In Supplemental Table 2, only cyclosporin A and rifampicin exhibited relatively low R and R' values and may lead to clinically relevant drug-drug interactions. On the other hand, pravastatin, an HMG-CoA reductase inhibitor, is not a cause of a severe drug-drug interaction based on OATP-mediated hepatic uptake because of its low plasma unbound concentration. As pravastatin is a potent HMG-CoA reductase inhibitor and is highly distributed to the liver, its target organ, a low plasma concentration is sufficient for its pharmacological effect, leading to a low risk of inhibition of transporter function (132). A small number of inhibitors with relatively low R values may be due to a lack of inhibition studies involving human OATP family transporters, and further studies may provide other inhibitors that cause clinically relevant drug-drug interactions. More inhibition studies on human OATP transporters are needed to allow the quantitative prediction of transporter-mediated drug-drug interactions.

MDR-Mediated Drug-Drug Interactions

MDR1 is expressed in the liver and kidney (7, 8, 15). Therefore, MDR1-mediated drug-drug interactions result in a reduction in renal and hepatobiliary excretion. It is also expressed in the intestine and the blood-brain barrier and, therefore, MDR1-mediated transport affects intestinal absorption and even distribution to the brain (7). MDR1-mediated drug-drug interactions cause complex effects. MDR1 has a broad substrate specificity and is inhibited by a large number of compounds. Quinidine is one MDR1 inhibitor (35). As the K_m value of quinidine for ATP-dependent efflux via MDR1 is approximately 5 μM (32), its K_i value for MDR1 can be assumed to be 5 μM . The therapeutic steady-state concentration of quinidine is approximately 4.5 μM and its unbound concentration is 0.59 μM . As MDR1 is an efflux transporter, the R value should be calculated using the unbound concentration of inhibitor in the cell. However, it is practically impossible to measure the intracellular unbound concentration of inhibitors in humans. Assuming the cell-to-medium concentration ratio to be 10 as a safety margin, the R value can be calculated to be $\frac{1}{1+10 \times 0.59/5} = 0.46$, suggesting that renal efflux will be reduced to at most 46% of the control. For hepatobiliary efflux, the blood concentration at the inlet to the liver should be used. The plasma concentration of quinidine at the inlet to the liver is calculated to be 4.6 μM using $Q_H = 1.6 \text{ liters min}^{-1}$, $F_a \cdot F_g =$

0.8, $k_a = 0.1 \text{ min}^{-1}$, and $f_u = 0.13$. Using this and assuming a cell-to-medium concentration ratio of 10, the calculated R value is $\frac{1}{1+10 \times 4.6/5} = 0.098$, suggesting that hepatobiliary excretion will be reduced to at most 9.8% of the control. Actually, both the hepatobiliary and renal clearances of digoxin have been reported to be reduced when concomitantly administered with quinidine (133).

MRP2-Mediated Drug-Drug Interactions

MRP2 also has a broad substrate specificity and is inhibited by a large number of therapeutic drugs, including cyclosporin A, daunomycin, etoposide, probenecid, and pravastatin (33, 134, 135). MRP2 functions as an efflux transporter for CPT-11 and its metabolites, SN-38 and SN-38 glucuronide (SN38-glu) (136). CPT-11 is excreted into the bile mainly via MDR1 and, to a minor extent, via MRP2, whereas SN-38 and SN38-glu are excreted via MRP2 (136). The biliary excretion of its metabolites causes severe diarrhea as a side effect (137, 138). To prevent this side effect, inhibition of MRP2-mediated transport by coadministration of its inhibitor may be effective. Horikawa et al. have investigated the inhibitory effects of several compounds on rat Mrp2 function (139). Among them, probenecid, sulfo-bromophthalein, and the glutathione-conjugate of sulfobromophthalein had potent inhibitory effects (139). The inhibitory effects of probenecid were also confirmed for the in vitro human biliary excretion of SN-38 with a K_i value of $42 \mu\text{M}$ (139). The same authors also confirmed these inhibitors of rat Mrp2 significantly reduced the biliary excretion of CPT-11, SN-38, and SN38-glu (140). They suggested the possibility of using MRP2 inhibitors such as probenecid to prevent the clinically observed toxicity of diarrhea by CPT-11.

EXAMPLES OF CLINICALLY RELEVANT DRUG-DRUG INTERACTIONS BASED ON RENAL AND HEPATOBILIARY TRANSPORT

In this section, examples of clinically relevant drug-drug interactions based on membrane transport in the kidney and the liver are described.

HMG-CoA Reductase Inhibitors Versus Cyclosporin A

As cerivastatin, a potent HMG-CoA reductase inhibitor (statin), is metabolized by two different enzymes, cytochrome P450 2C8 (CYP2C8) and 3A4, the likelihood of a severe drug-drug interaction was believed to be low (141). However, the plasma concentration of cerivastatin was reported to be increased when coadministered with cyclosporin A (142).

The plasma AUC and maximum plasma concentration of cerivastatin increased by four- and fivefold, respectively, when concomitantly administered with cyclosporin A (142). Our group investigated the mechanism underlying this drug-drug interaction (62). We have shown that the transporter-mediated uptake of

cerivastatin is inhibited by cyclosporin A at a low concentration (K_i was $0.3 \sim 0.7 \mu\text{M}$), whereas the in vitro metabolism of cerivastatin is inhibited with an IC_{50} value of more than $30 \mu\text{M}$, suggesting that this clinically relevant drug-drug interaction was caused by a transporter-mediated process rather than a metabolic one (62). The unbound concentration of cyclosporin A in the circulating blood and at the inlet to the liver, calculated by Equation 13, is, at most, $0.1 \mu\text{M}$ and $0.6 \mu\text{M}$, respectively, which may explain the clinically relevant drug-drug interaction, although there may be other mechanisms involved (62). We also showed that the OATP-C/OATP2 [OATP1B1]-mediated transport of cerivastatin was inhibited by cyclosporin A with a K_i value of less than $0.2 \mu\text{M}$ (Figure 7) (62).

In addition to cerivastatin, the plasma concentrations of pravastatin, pitavastatin, and HMG-CoA reductase inhibitory activity of atorvastatin are reported to be affected by concomitantly administered cyclosporin A (143–145). Among them, pravastatin and pitavastatin undergo only minimal metabolism, and the likelihood of a drug-drug interaction owing to this is quite low. As these statins are substrates of OATP-C/OATP2 [OATP1B1], interactions with cyclosporin A may also be caused by a transporter-based mechanism (55, 56, 121). Interaction between atorvastatin and cyclosporin A may have occurred by a transporter-mediated




Figure 7 Transcellular transport of cerivastatin (CER) mediated by OATP-C/OATP2 [OATP1B1] and MRP2 and the inhibitory effect of cyclosporin A. (a) Transcellular transport of [^{14}C]CER in OATP-C/OATP2 [OATP1B1] and MRP2 double-transfected MDCK cells (*closed squares*) and in vector-transfected cells (*closed circles*) was examined. Addition of cyclosporin A ($10 \mu\text{M}$) inhibited OATP-C/OATP2 [OATP1B1]- and MRP2-mediated transport of CER (*open squares*), whereas it did not change the transcellular transport in vector transfected cells (*open circles*). (b) Cyclosporin A inhibited the transcellular transport ($\text{PS}_{B \rightarrow A}$) in a concentration-dependent manner. The IC_{50} value obtained in this experimental system was $0.084 \pm 0.015 \mu\text{M}$. ** $p < 0.01$, *** $p < 0.001$.

TABLE 1 Kinetic parameters of HMG-CoA reductase inhibitors coadministered with cyclosporin A

HMG-CoA reductase inhibitors	Cyclosporin A (+/–)				Major clearance mechanism	Reference
	Cmax [ng/mL]	Ratio	AUC [ng · h/mL]	Ratio		
Simvastatin	18.9/2.5**	7.56	78.1/9.8**	7.97	CYP3A4	193
	20.6/9.9*	2.08	101/39.6*	2.55		
Pravastatin	223/28.0	7.95	1300/57.1***		OATP-C	143
Fluvastatin	155/119	1.30	373/192	1.94	CYP2C9	195
Cerivastatin	7.82/1.56	5.01	36.2/9.53	3.80	CYP2C8/ 3A4OATP-C	142
Atorvastatin	58.0/8.8#*	6.59	595/79.9#*	7.45	CYP3A4-OATP-C	145
Pitavastatin	179/27.6***	6.49	347/76.9***	4.51	OATP-C	144

#ng eq./mL or ng eq. · h/mL

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

and metabolism-based mechanism as atorvastatin is metabolized by CYP3A4 and cyclosporin A inhibits CYP3A4-mediated metabolism (146). In Table 1, we summarize pharmacokinetic interactions between HMG-CoA reductase inhibitors and cyclosporin A.

HMG-CoA Reductase Inhibitors Versus Gemfibrozil

Gemfibrozil also interacts with a wide range of statins (Table 2). In particular, interactions with cerivastatin have been reported to cause the severe side effect of myotoxicity, including lethal rhabdomyolysis (147). In addition, pharmacokinetic interaction between cerivastatin and gemfibrozil was reported (148, 149). Although our group examined the inhibitory effects of gemfibrozil and its major metabolites on the OATP-C/OATP2 [OATP1B1]-mediated uptake of cerivastatin, we found gemfibrozil and its glucuronide inhibited it with IC_{50} values of 72 and 24 μ M, respectively, which were higher than their therapeutic unbound concentrations, suggesting a low possibility of a transporter-mediated drug-drug interaction (150). On the other hand, an interaction with rosuvastatin was reported to be caused by the inhibition of OATP-C/OATP2 [OATP1B1]-mediated uptake by Schneck et al. (151). In their report, gemfibrozil inhibited the OATP-C/OATP2 [OATP1B1]-mediated transport of cerivastatin with a low IC_{50} value of 4 μ M (151). Although it is still higher than the therapeutic unbound concentration of cerivastatin, this value is lower than that we have obtained (150). This gap may be partly due to the difference in the experimental system, i.e., we used transporter-expressing MDCK cells, whereas Schneck et al. used cRNA-injected

TABLE 2 Kinetic parameters of HMG-CoA reductase inhibitors coadministered with gemfibrozil

HMG-CoA reductase inhibitors	Gemfibrozil (+/–)				Major clearance mechanism	Reference
	Cmax [ng/mL]	Ratio	AUC [ng · h/mL]	Ratio		
Lovastatin	2.38/2.69	0.885	33.1/34.4	0.962	CYP3A4	196
Simvastatin	6.15/6.87	0.895	36.2/25.2**	1.44	CYP3A4	197
Pravastatin	120/66.3*	1.81	281/139*	2.02	OATP-C	198
Fluvastatin	54.3/48.4	1.12	213/227	0.938	CYP2C9	199
Cerivastatin	8.0/3.2**	2.5	91.1/20.9***	4.36	CYP2C8/3A4	148
					OATP-C	
	2.93/1.61	1.82	41.9/9.92	4.22		149
Pitavastatin	no data	1.30	no data	1.45	OATP-C	200
Rosuvastatin	109/49.5	2.20	771/410	1.88	CYP2C9	151
					OATP-C	

*p<0.05, **p<0.01, ***p<0.001

Xenopus laevis oocytes (150, 151). We also analyzed the inhibitory effects of gemfibrozil and its metabolites on the P450-mediated metabolism of cerivastatin and found that gemfibrozil and its glucuronide inhibited the CYP2C8-mediated metabolism with IC₅₀ values of 28 and 4 μM, respectively (150). They are still higher than the therapeutic unbound concentrations in the circulating blood. However, there are reports that, in rat perfusion studies, gemfibrozil-1-O-glucuronide is actively taken up into the liver and accumulates there (152–154). If this also took place in human liver, the concentrated gemfibrozil-1-O-glucuronide might act as an inhibitor of CYP2C8-mediated metabolism, leading to a drug-drug interaction. In this case, a transporter plays an important role, i.e., an inhibitor of the metabolism leading to accumulation in the liver via transporter-mediated uptake. Our hypothesis that interaction with gemfibrozil is not a transporter-mediated one, but a metabolism-mediated one, is supported by the fact that gemfibrozil does not cause a severe interaction with pravastatin and pitavastatin, which are mainly cleared by the OATP-C/OATP2 [OATP1B1]-mediated hepatic uptake (Table 2). Therefore, we should also be more cautious about drug-drug interactions when inhibitors of the metabolism are substrates of hepatic uptake transporters (Figure 8).

Digoxin Versus Quinidine and Quinine

Digoxin undergoes biliary and renal excretion. Drug-drug interactions between digoxin and quinidine and between digoxin and quinine (a stereoisomer of quinidine) have been reported by Hedmann et al. (133). Quinidine reduced the renal and biliary excretion of digoxin, whereas quinine reduced only the biliary excretion of digoxin (133).

Because quinidine is a well-known P-gp inhibitor, its effect on biliary and urinary excretion may be related to P-gp (MDR1)- mediated transport (35). As




Figure 8 Possible mechanism of drug-drug interaction between cerivastatin and gemfibrozil. Gemfibrozil-1-O-glucuronide is actively taken up via transporter(s) and accumulates in the liver. In the liver, its concentration is hypothesized to be high enough to inhibit the P450-mediated metabolism of cerivastatin.

described in MDR-Mediated Drug-Drug Interactions (above), the K_i value of quinidine for the MDR1-mediated efflux can be assumed to be 5 μM . On the other hand, the steady-state plasma concentration of quinidine in this study was 4.5 μM , with a protein unbound fraction of 0.13. Therefore, the protein unbound concentration in the circulating blood is estimated to be 0.59 μM . The unbound concentration of quinidine at the inlet to the liver estimated by Equation 13 is 4.6 μM using $Q_H = 1.6 \text{ liters min}^{-1}$, $F_a \cdot F_g = 0.8$, and $k_a = 0.1 \text{ min}^{-1}$. With a safety margin of 1 ~ 10 as a cell-to-medium concentration ratio, the estimated reduction in the renal excretion of digoxin is 46% to 89% of the control, and the estimated reduction in the hepatobiliary excretion of digoxin is 9.8% to 52% of the control. In clinical situations, the hepatobiliary excretion was reduced to 42% of the control, whereas the renal excretion was reduced to 60% of the control, which was within the predicted range (133).

In rat hepatocytes, the inhibitory effect on the uptake of digoxin was more potent for quinine than for quinidine, and the same tendency was observed using the rat Oatp2 [Oatp1a4] expression system (122, 155). Therefore, the mechanism of the drug-drug interaction between digoxin and quinine may be caused by the inhibition of the transporter-mediated uptake. However, there is a study that shows that both quinine and quinidine had no inhibitory effects on the uptake of digoxin into isolated human hepatocytes, although both of them inhibited the uptake of digoxin into rat hepatocytes (156).

Drug-Drug Interactions Between Cephalosporin Antibiotics and Probenecid

There are many reports on the drug-drug interactions between cephalosporin antibiotics and probenecid (157). As both cephalosporins and probenecid interact with OAT family transporters, some of these drug-drug interactions may be due to an OAT-mediated uptake process. Most cephalosporins, which may be partly mediated by OAT family transporters are excreted in the urine. The elimination rates of cephazedone, cefazolin, cefalexin, cefradine, cefaclor, cefmetazole, cefoxitin, cefuroxime, cefmenoxime, ceftizoxime, and ceftriaxone were significantly reduced by coadministration of probenecid, which may be partly caused by the inhibition of their renal excretions (157).

Marino & Dominguez-Gil have shown that the pharmacokinetics of cefadroxil is altered by coadministration of probenecid (158). In their report, the peak concentration and half-life of cefadroxil was increased 1.4- and 1.3-fold, respectively, following coadministration of probenecid. Its urinary excretion rate constant falls by 58%, supporting the possibility of drug-drug interaction at the renal excretion. Supplemental Table 1 suggests that OAT1- and OAT3-mediated transport should be decreased to at most 25%–47% and 25%–69% of the control, and, therefore, it may be partly explained by the OAT-mediated drug-drug interaction.

Probenecid has also been shown to alter the plasma concentrations of cefamandole and ceftriaxone (159). The maximum plasma concentration and half-life of cefamandole were increased 6- and 1.8-fold by coadministration of probenecid (159). Also, 71% of cefamandole is excreted in the urine, and this was reduced to 66% of the control (159). The elimination of ceftriaxone was slightly affected by coadministration of probenecid (160). Probenecid reduced the serum clearance of ceftriaxone to 73% of the control (160). It reduced the renal and nonrenal clearance to 80% and 68% of the control, respectively, suggesting that this drug-drug interaction is, to a minor extent, due to renal excretion (160).

Drug-Drug Interaction Between Methotrexate and NSAIDs

To date, there are reports that coadministration of MTX with penicillin, probenecid, and NSAIDs cause drug-drug interactions and several potential sites for these DDI have been reported: an increase in the protein unbound fraction of MTX, a decrease in the urine flow rate resulting from the inhibition of prostaglandin synthesis, and inhibition of the renal tubular secretion of MTX (161–164). Nozaki et al. analyzed the uptake mechanism of MTX in rat kidney slices and examined the effects of NSAIDs on its uptake (165). They showed that rat Oat3 and reduced folate carrier 1 (RFC-1) equally contribute to the renal uptake (30% each), with the remaining fraction being accounted for by passive diffusion and/or adsorption, whereas rOat1 makes only a limited contribution (165). Many NSAIDs inhibited both rOat3- and RFC-1-mediated uptake of MTX, but the K_i value for Oat3 was lower than that for RFC-1 (165). At their therapeutic concentrations, they inhibited only Oat3-mediated uptake of MTX. Therefore, the affect of NSAIDs on the renal uptake of

MTX is expected to be nonextensive and partial. Many NSAIDs also inhibit human OAT3-mediated uptake of MTX with therapeutic relevant plasma concentrations of unbound drugs (26). However, also in humans, the contribution of OAT3 to the total renal uptake of MTX needs to be clarified for the identification of the mechanism of the clinically relevant DDI.

CONCLUSION

In addition to phase I and phase II enzymes, transporters also play an important role in drug elimination and distribution. Therefore, it is possible that transporter-mediated drug-drug interactions alter pharmacokinetics, and could result in severe side effects.

A large number of transporters have been characterized in rodents and humans, and the mechanism of the membrane transport of several compounds including endogenous compounds and therapeutic drugs has been clarified. However, the transport mechanism of most therapeutic drugs remains unknown. To predict a transporter-mediated drug-drug interaction, the transporters involved in the membrane transport of the drug need to be characterized. As multiple transporters have been characterized in the kidney and liver and their expression systems are available, it should be possible to predict a transporter-mediated drug-drug interaction by using these systems with the information of the contribution made by each transporter to the net transport in the kidney and liver.

We have estimated the possibility of a transporter-mediated drug-drug interaction from the R value, calculated using the maximum unbound concentration of inhibitors. This method may avoid false negative predictions of drug-drug interactions. In conclusion, greater awareness of the possibility of transporter-mediated drug-drug interactions is necessary.

**The *Annual Review of Pharmacology and Toxicology* is online at
<http://pharmatox.annualreviews.org>**

LITERATURE CITED

1. Petzinger E. 1994. Transport of organic anions in the liver. An update on bile acid, fatty acid, monocarboxylate, anionic amino acid, cholephilic organic anion, and anionic drug transport. *Rev. Physiol. Biochem. Pharmacol.* 123:47–211
2. Oude Elferink RPJ, Meijer DKF, Kuipers F, Jansen PLM, Groen AK, Groothuis GMM. 1995. Hepatobiliary secretion of organic compounds; molecular mechanism of membrane transport. *Biochem. Biophys. Acta* 1241:215–68
3. Yamazaki M, Suzuki H, Sugiyama Y. 1996. Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. *Pharm. Res.* 13:497–513
4. Okudaira N, Sugiyama Y. 1996. Use of an isolated perfused kidney to assess renal clearance of drugs: information obtained in steady-state and non-steady-state experimental systems. In *Models for Assessing Drug Absorption and Metabolism*, ed RT Borchard, PL Smith, G Wilson, pp. 211–38. New York: Plenum Press

5. Giacomini KM, Hsyu PH, Gisclon JG. 1988. Renal transport of drugs: an overview of methodology with application to cimetidine. *Pharm. Res.* 5:465–71
6. van Aubel RAMH, Masereeuw R, Russel FGM. 2000. Molecular pharmacology of renal organic anion transporters. *Am. J. Physiol. Renal Physiol.* 279:F216–32
7. Kusuvara H, Sugiyama Y. 2002. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. *J. Control. Release* 78:43–54
8. Kusuvara H, Suzuki H, Sugiyama Y. 1998. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. *J. Pharm. Sci.* 87:1025–40
9. Suzuki H, Sugiyama Y. 2000. Transport of drugs across the hepatic sinusoidal membrane: sinusoidal drug influx and efflux in the liver. *Semin. Liver Dis.* 20:251–63
10. Inui K, Masuda S, Saito H. 2000. Cellular and molecular aspects of drug transport in the kidney. *Kidney Int.* 58:944–58
11. Dresser MJ, Leabman MK, Giacomini KM. 2001. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. *J. Pharm. Sci.* 90:397–421
12. Sweet DH, Bush KT, Nigam SK. 2001. The organic anion transporter family: from physiology to ontogeny and the clinic. *Am. J. Physiol. Renal Physiol.* 281: F197–205
13. Sekine T, Cha SH, Endou H. 2000. The multispecific organic anion transporter (OAT) family. *Pflugers Arch.* 440:337–50
14. Koepsell H, Gorboulev V, Arndt P. 1999. Molecular pharmacology of organic cation transporters in the kidney. *J. Membr. Biol.* 167:103–17
15. Mizuno N, Sugiyama Y. 2002. Drug transporters: their roles and importance in the selection and development of new drugs. *Drug Metab. Pharmacokin.* 17:93–108
16. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. 1997. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. *Hepatology* 26:1667–77
17. Pang KS, Rowland M. 1977. Hepatic clearance of drugs I: theoretical considerations of a “well-stirred” model and a “parallel-tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. *J. Pharmacokin. Biopharm.* 5:625–53
18. Pang KS, Gillette R. 1978. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: difference between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. *J. Pharmacol. Exp. Ther.* 207:178–94
19. Miyauchi S, Sugiyama Y, Sawada Y, Morita K, Iga T, et al. 1987. Kinetics of hepatic transport of 4-methylumbelliferone in rats: analysis by multiple indicator dilution method. *J. Pharmacokin. Biopharm.* 15:25–38
20. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. 1997. Expression cloning and characterization of a novel multispecific organic anion transporter. *J. Biol. Chem.* 272:18526–29
21. Hosoyamada M, Sekine T, Kanai Y, Endou H. 1999. Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. *Am. J. Physiol. Renal Physiol.* 276:F122–28
22. Sun W, Wu RR, van Poelje PD, Erion MD. 2001. Isolation of a family of organic anion transporters from human liver and kidney. *Biochem. Biophys. Res. Comm.* 283:417–22
23. Race JE, Grassl SM, Williams WJ, Holtzman EJ. 1999. Molecular cloning and characterization of two novel human renal organic anion transporters (hOAT1 and hOAT3). *Biochem. Biophys. Res. Commun.* 255:508–14

24. Cha SH, Sekine T, Kusuha H, Yu E, Kim JY, et al. 2000. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. *J. Biol. Chem.* 275:4507–12
25. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, et al. 2001. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. *Mol. Pharmacol.* 59:1277–86
26. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, et al. 2002. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. *J. Pharmacol. Exp. Ther.* 302:666–71
27. Takeda M, Khamdang S, Narikawa S, Kimura H, Kobayashi Y, et al. 2002. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. *J. Pharmacol. Exp. Ther.* 300:918–24
28. Jung KY, Takeda M, Kim DK, Tojo A, Narikawa S, et al. 2001. Characterization of ochratoxin A transport by human organic anion transporters. *Life Sci.* 69:2123–35
29. Lecureur V, Sun D, Hargrove P, Schuetz EG, Kim RB, et al. 2000. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. *Mol. Pharmacol.* 57:24–35
30. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, et al. 2001. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. *J. Pharmacol. Exp. Ther.* 296:723–35
31. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, et al. 1992. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. *Proc. Natl. Acad. Sci. USA* 89:8472–76
32. Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. *Pharm. Res.* 18:1660–68
33. Guo A, Marinaro W, Hu P, Sinko PJ. 2002. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). *Drug Metab. Dispos.* 30:457–63
34. Walle UK, Walle T. 1998. Taxol transport by human intestinal epithelial Caco-2 cells. *Drug Metab. Dispos.* 26:343–46
35. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, et al. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). *J. Pharmacol. Exp. Ther.* 263:840–45
36. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, et al. 1992. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. *J. Biol. Chem.* 267:24248–52
37. Ganapathy ME, Brandsch M, Prasad PD, Ganapathy V, Leibach FH. 1995. Differential recognition of beta-lactam antibiotics by intestinal and renal peptide transporters, PEPT 1 and PEPT 2. *J. Biol. Chem.* 270:25672–77
38. Smith DE, Pavlova A, Berger UV, Hediger MA, Yang T, et al. 1998. Tubular localization and tissue distribution of peptide transporters in rat kidney. *Pharm. Res.* 15:1244–49
39. Shen H, Smith DE, Yang T, Huang YG, Schnermann JB, et al. 1999. Localization of PEPT1 and PEPT2 proton-coupled oligopeptide transporter mRNA and protein in rat kidney. *Am. J. Physiol. Renal Physiol.* 276:F658–65
40. Tsuji A. 2002. Transporter-mediated drug interactions. *Drug. Metabol. Pharmacokin.* 17:253–74

41. Han HK, Rhie JK, Oh DM, Saito G, Hsu CP, et al. 1999. CHO/hPEPT1 cells over-expressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. *J. Pharm. Sci.* 88:347–50
42. Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, et al. 1997. Cloning and characterization of two human polyspecific organic cation transporters. *DNA Cell. Biol.* 16:871–81
43. Zhang L, Schaner ME, Giacomini KM. 1998. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). *J. Pharmacol. Exp. Ther.* 286:354–61
44. Dudley AJ, Bleasby K, Brown CD. 2000. The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK1 cell monolayers. *Br. J. Pharmacol.* 131:71–79
45. Busch AE, Karbach U, Miska D, Gorboulev V, Akhoundova A, et al. 1998. Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. *Mol. Pharmacol.* 54:342–52
46. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K. 2002. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. *J. Am. Soc. Nephrol.* 13:1703–10
47. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, et al. 1997. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. *FEBS Lett.* 419:107–11
48. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, et al. 1999. Novel membrane transporter OCTN1 mediates multi-specific, bidirectional, and pH-dependent transport of organic cations. *J. Pharmacol. Exp. Ther.* 289:768–73
49. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, et al. 1998. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. *J. Biol. Chem.* 273:20378–82
50. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, et al. 1999. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. *J. Pharmacol. Exp. Ther.* 290:1482–92
51. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, et al. 1999. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. *Nat. Genet.* 21:91–94
52. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, et al. 1999. Na⁺-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. *J. Pharmacol. Exp. Ther.* 291:778–84
53. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, et al. 2000. β -lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. *J. Biol. Chem.* 275:1699–707
54. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, et al. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. *Biochem. Biophys. Res. Commun.* 273:251–60
55. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasaseville V, et al. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J. Biol. Chem.* 274:37161–68
56. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, et al. 2001. Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human

- hepatocytes. *J. Pharmacol. Exp. Ther.* 297:861–67
57. König J, Cui Y, Nies AT, Keppler D. 2000. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. *Am. J. Physiol. Gastrointest. Liver Physiol.* 278:G156–64
58. König J, Cui Y, Nies AT, Keppler D. 2000. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. *J. Biol. Chem.* 275:23161–68
59. Jacquemin E, Hagenbuch B, Stieger B, Wolkoff AW, Meier PJ. 1994. Expression cloning of a rat liver Na⁺-independent organic anion transporter. *Proc. Natl. Acad. Sci. USA* 91:133–37
60. Noé B, Hagenbuch B, Stieger B, Meier PJ. 1997. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. *Proc. Natl. Acad. Sci. USA* 94:10346–50
61. Cattori V, Hagenbuch B, Hagenbuch N, Stieger B, Ha R, et al. 2000. Identification of organic anion transporting polypeptide 4 (Oatp4) as a major full-length isoform of the liver-specific transporter-1 (rlst-1) in rat liver. *FEBS Lett.* 474:242–45
62. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. *J. Pharmacol. Exp. Ther.* 304:610–16
63. Pang KS, Wang PJ, Chung AYK, Wolkoff AW. 1998. The modified dipeptide enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein. *Hepatology* 28:1341–46
64. Ishizuka H, Konno K, Naganuma H, Nishimura K, Kouzuki H, et al. 1998. Transport of temocaprilat into rat hepatocytes: role of organic anion transporting polypeptide. *J. Pharmacol. Exp. Ther.* 287:37–42
65. Kullak-Ublick GA, Ismail MG, Stieger B, Landmann L, Huber R, et al. 2001. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. *Gastroenterology* 120:525–33
66. Jansen PL, Peters WH, Lamers WH. 1985. Hereditary chronic conjugated hyperbilirunemia in mutant rats caused by defective hepatic anion transport. *Hepatology* 5:573–79
67. Hosokawa S, Tagaya O, Mikami T, Nozaki Y, Kawaguchi Y, et al. 1992. A new rat mutant with chronic conjugated hyperbilirunemia and renal glomerular lesions. *Lab. Animal Sci.* 42:27–34
68. Muller M, Jansen PL. 1997. Molecular aspects of hepatobiliary transport. *Am. J. Physiol. Gastrointest. Liver Physiol.* 272:G1285–303
69. Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK, et al. 1995. Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. *Biochim. Biophys. Acta* 1241:215–68
70. Stieger B, Meier PJ. 1998. Bile acid and xenobiotic transporters in liver. *Curr. Opin. Cell. Biol.* 10:462–67
71. Suzuki H, Sugiyama Y. 1998. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2. *Semin. Liver Dis.* 18:359–76
72. König J, Nies AT, Cui Y, Leier I, Keppler D. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. *Biochim. Biophys. Acta* 1461:377–94
73. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, et al. 1996. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. *Science* 271:1126–28
74. Ito K, Suzuki H, Hirohashi T, Kume K, Shimizu T, et al. 1997. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. *Am. J. Physiol. Gastrointest. Liver Physiol.* 272:G16–22

75. Buchler M, König J, Brom M, Kartenbeck J, Spring H, et al. 1996. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. *J. Biol. Chem.* 271:15091–98
76. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. *Cancer Res.* 56:4124–29
77. Borst P, Evers R, Kool M, Wijnholds J. 1999. The multidrug resistance protein family. *Biochim. Biophys. Acta* 1461:347–57
78. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K, Wada M. 1999. Multidrug resistance-associated protein subfamily transporters and drug resistance. *Anti-cancer Drug Des.* 14:123–31
79. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B, et al. 1997. ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. *Biochem. J.* 327:305–10
80. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, et al. 1999. Primary active transport of organic anions on bile canalicular membrane in humans. *Am. J. Physiol. Gastrointest. Liver Physiol.* 276:G1153–64
81. Cui Y, König J, Buchholz JK, Spring H, Leier I, et al. 1999. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. *Mol. Pharmacol.* 55:929–37
82. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, et al. 1999. Primary active transport of organic anions on bile canalicular membrane in humans. *Am. J. Physiol. Gastrointest. Liver Physiol.* 276:G1153–64
83. Paulusma CC, van Geer MA, Evers R, Heijn M, Ottenhoff R, et al. 1999. Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport of reduced glutathione. *Biochem. J.* 338:393–401
84. Ryu S, Kawabe T, Nada S, Yamaguchi A. 2000. Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. *J. Biol. Chem.* 275:39617–24
85. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. 2002. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). *J. Biol. Chem.* 277:6497–503
86. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, et al. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. *Cancer Res.* 59:2532–35
87. Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? *Pharm. Res.* 19:773–79
88. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, et al. 1999. Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. *Mol. Pharmacol.* 56:1219–28
89. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y. 2002. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. *Pharm. Res.* 19:34–41
90. Zeng H, Liu G, Rea PA, Kruh GD. 2000. Transport of amphipathic anions by human multidrug resistance protein 3. *Cancer Res.* 60:4779–84

91. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, et al. 1998. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc. Natl. Acad. Sci. USA* 95:15665–70
92. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. 1998. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res.* 58:5337–39
93. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, et al. 1999. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells. *Cancer Res.* 59:8–13
94. Maliapaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg ACLM, et al. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res.* 61:3458–64
95. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. 2003. ABCG2 transports sulfated conjugates of steroids and xenobiotics. *J. Biol. Chem.* 278:22644–49
96. Urakami Y, Nakamura N, Takahashi K, Okuda M, Saito H, et al. 1999. Gender differences in expression of organic cation transporter OCT2 in rat kidney. *FEBS Lett.* 461:339–42
97. Hasegawa M, Kusuvara H, Sugiyama D, Ito K, Ueda S, et al. 2002. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. *J. Pharmacol. Exp. Ther.* 300:746–53
98. Hori R, Ishikawa Y, Takano M, Okano T, Kitazawa S, et al. 1982. The interaction of cephalosporin antibiotics with renal cortex of rats: accumulation to cortical slices and binding to purified plasma membranes. *Biochem. Pharmacol.* 31:2267–72
99. Terada T, Sawada K, Ito T, Saito H, Hashimoto Y, et al. 2000. Functional expression of novel peptide transporter in renal basolateral membranes. *Am. J. Physiol. Renal Physiol.* 279:F851–57
100. Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, et al. 1999. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. *J. Pharmacol. Exp. Ther.* 290:1107–15
101. Ishigami M, Tokui T, Komai T, Tsukahara K, Yamazaki M, et al. 1995. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. *Pharm. Res.* 12:1741–45
102. Madan A, DeHaan R, Mudra D, Carroll K, LeCluyse E, Parkinson A. 1999. Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytes. *Drug Metab. Dispos.* 27:327–35
103. Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. 1997. Pre-clinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. *Chem. Biol. Interact.* 107:5–16
104. Li AP, Lu C, Brent JA, Pham C, Fackett A, et al. 1999. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. *Chem. Biol. Interact.* 121:17–35
105. Li AP, Gorycki PD, Hengstler JG, Kedderis GL, Koebe HG, et al. 1999. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. *Chem. Biol. Interact.* 121:117–23
106. Shitara Y, Li AP, Kato Y, Lu C, Ito K, et al. 2003. Function of uptake transporters for taurocholate and estradiol 17 β -D-glucuronide in cryopreserved human hepatocytes. *Drug Metab. Pharmacokin.* 18:33–41
107. Olinga P, Hof IH, Merema MT, Smit M, de Jager MH, et al. 2001. The applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake.

- J. Pharmacol. Toxicol. Methods* 45:55–63
108. Shigematsu A, Motoji N, Momose Y, Iida A, Higashi N. 2000. Viability of liver slices exhibiting absorption, metabolism, and elimination of substrates in culture medium. *Exp. Mol. Pathol.* 69:119–43
 109. Pritchard JB, Miller DS. 1993. Mechanisms mediating renal secretion of organic anions and cations. *Physiol. Rev.* 73:765–96
 110. Murer H, Gmaj P, Steiger B, Hagenbuch B. 1989. Transport studies with renal proximal tubular and small intestinal brush border and basolateral membrane vesicles: vesicle heterogeneity, coexistence of transport system. *Methods Enzymol.* 172:346–64
 111. Boyer JL, Meier PJ. 1990. Characterizing mechanisms of hepatic bile acid transport utilizing isolated membrane vesicles. *Methods Enzymol.* 192:517–33
 112. Kinne-Saffran E, Kinne RK. Isolation of luminal and cotraluminal plasma membrane vesicles from kidney. *Methods Enzymol.* 191:450–69
 113. Meier PJ, Boyer JL. 1990. Preparation of basolateral (sinusoidal) and canalicular plasma membrane vesicles for the study of hepatic transport processes. *Methods Enzymol.* 192:534–45
 114. Meier PJ, St Meier-Abt A, Barrett C, Boyer JL. 1984. Mechanisms of taurocholate transport in canalicular and basolateral rat liver plasma membrane vesicles. Evidence for an electrogenic canalicular organic anion carrier. *J. Biol. Chem.* 259:10614–22
 115. Cui Y, Konig J, Keppler D. 2001. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCB2. *Mol. Pharmacol.* 60:934–43
 116. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, et al. 1997. Normal viability and altered pharmacokinetics in mice lacking *mdr1*-type (drug-transporting) P-glycoproteins. *Proc. Natl. Acad. Sci. USA* 94:4028–33
 117. Hagenbuch B, Scharschmidt BF, Meier PJ. 1996. Effect of antisense oligonucleotides on the expression of hepatocellular bile acid and organic anion uptake systems in *Xenopus laevis* oocytes. *Biochem. J.* 316:901–4
 118. Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, et al. 1997. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. *J. Pharm. Pharmacol.* 49:796–801
 119. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. 1998. Contribution of sodium taurocholate co-transporting polypeptide to the uptake of its possible substrates into rat hepatocytes. *J. Pharmacol. Exp. Ther.* 286:1043–50
 120. Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. 1999. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. *J. Pharmacol. Exp. Ther.* 288:627–34
 121. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. *J. Pharmacol. Exp. Ther.* 311:139–46
 122. Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T. 2002. Comparative inhibitory effects of different compounds on rat *oatpl* (*Slc21a1*)- and *oatp2* (*Slc21a5*)-mediated transport. *Pharm. Res.* 19:147–53
 123. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, et al. 1998. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. *Pharmacol. Rev.* 50:387–412
 124. Ito K, Iwatsubo T, Kanamitsu S, Nakajima Y, Sugiyama Y. 1998. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and

- transport. *Annu. Rev. Pharmacol. Toxicol.* 38:461–99
125. Ueda K, Kato Y, Komatsu K, Sugiyama Y. 2001. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. *J. Pharmacol. Exp. Ther.* 297:1036–43
126. Saito H, Masuda S, Inui K. 1996. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. *J. Biol. Chem.* 271:20719–25
127. Masuda S, Saito H, Inui K. 1997. Interactions of nonsteroidal anti-inflammatory drugs with rat renal organic anion transporter, OAT-K1. *J. Pharmacol. Exp. Ther.* 283:1039–42
128. Masuda S, Takeuchi A, Saito H, Hashimoto Y, Inui K. 1999. Functional analysis of rat renal organic anion transporter OAT-K1: bidirectional methotrexate transport in apical membrane. *FEBS Lett.* 459:128–32
129. Masuda S, Ibaramoto K, Takeuchi A, Saito H, Hashimoto Y, et al. 1999. Cloning and functional characterization of a new multispecific organic anion transporter, OAT-K2, in rat kidney. *Mol. Pharmacol.* 55:743–52
130. Takeuchi A, Masuda S, Saito H, Abe T, Inui K. 2001. Multispecific substrate recognition of kidney-specific organic anion transporters OAT-K1 and OAT-K2. *J. Pharmacol. Exp. Ther.* 299:261–67
131. Lu R, Kanai N, Bao Y, Wolkoff AW, Schuster VL. 1996. Regulation of renal oatp mRNA expression by testosterone. *Am. J. Physiol. Renal Physiol.* 270:F332–37
132. Yamazaki M, Tokui T, Ishigami M, Sugiyama Y. 1996. Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system. *Biopharm. Drug Dispos.* 17:775–89
133. Hedman A, Angelin B, Arvidsson A, Dahlqvist R, Nilsson B. 1990. Interactions in the renal and biliary elimination of digoxin: stereoselective difference between quinine and quinidine. *Clin. Pharmacol. Ther.* 47:20–26
134. Bohme M, Jedlitschky G, Leier I, Buchler M, Keppler D. 1994. ATP-dependent export pumps and their inhibition by cyclosporins. *Adv. Enzyme Regul.* 34:371–80
135. Versantvoort CH, Broxterman HJ, Lankelma J, Feller N, Pinedo HM. 1994. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. *Biochem. Pharmacol.* 48:1129–36
136. Chu XY, Kato Y, Niinuma K, Sudo KI, Hokusui H, et al. 1997. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. *J. Pharmacol. Exp. Ther.* 281:304–14
137. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, et al. 1993. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. *Jpn. J. Cancer Res.* 84:697–702
138. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, et al. 1994. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. *Cancer Res.* 54:3723–25
139. Horikawa M, Kato Y, Tyson CA, Sugiyama Y. 2002. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. *Drug Metab. Pharmacokin.* 17:23–33
140. Horikawa M, Kato Y, Sugiyama Y. 2002. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. *Pharm. Res.* 19:1345–53

141. Mück W. 2000. Clinical pharmacokinetics of cerivastatin. *Clin. Pharmacokinet.* 39:99–116
142. Mück W, Mai I, Fritsche L, Ochmann K, Rohde G, et al. 1999. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporin-treated kidney transplant recipients. *Clin. Pharmacol. Ther.* 65:251–61
143. Regazzi MB, Campana IC, Raddato V, Lesi C, Perani G, et al. 1993. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. *Transplant. Proc.* 25:2732–34
144. Hasunuma T, Nakamura M, Yachi T, Arisawa N, Fukushima K, et al. 2003. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. *J. Clin. Ther. Med.* 19:381–89
145. Asberg A, Hartmann A, Fjeldsa E, Bergan S, Holdaas H. 2001. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. *Am. J. Transplant.* 1: 382–86
146. Lennernas H. 2003. Clinical pharmacokinetics of atorvastatin. *Clin. Pharmacokinet.* 42:1141–60
147. Bruce-Joyce J, Dugas JM, MacCausland OE. 2001. Cerivastatin and gemfibrozil-associated rhabdomyolysis. *Ann. Pharmacother.* 35:1016–19
148. Mueck W, Frey R, Boix O, Voith B. 2001. Gemfibrozil/cerivastatin interaction. *AAPS PharmSci.* 3(Suppl.):3566 (Abstr.)
149. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. *Clin. Pharmacol. Ther.* 72:685–91
150. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the OATP2(OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin—analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. *J. Pharmacol. Exp. Ther.* 311:228–36
151. Schneck DW, Birmingham BK, Zaklikowski JA, Mitchell PD, Wang Y, et al. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. *Clin. Pharmacol. Ther.* 75:455–63
152. Sallustio BC, Fairchild BA, Shanahan K, Evans AM, Nation RL. 1996. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. *Drug Metab. Dispos.* 24:984–89
153. Sabordo L, Sallustio BC, Evans AM, Nation RL. 1998. Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil β -D-glucuronide: effects of dibromosulphothalein on membrane transport and aglycone formation. *J. Pharmacol. Exp. Ther.* 288:414–20
154. Sabordo L, Sallustio BC, Evans AM, Nation RL. 2000. Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil- β -D-glucuronide: effects of clofibrilic acid, acetaminophen, and acetaminophen glucuronide. *J. Pharmacol. Exp. Ther.* 295: 44–50
155. Hedman A, Meijer DK. 1998. Stereospecific inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. *J. Pharm. Sci.* 87:457–61
156. Olinga P, Merema M, Hof IH, Slooff MJ, Proost JH, et al. 1998. Characterization of the uptake of rocuronium and digoxin in human hepatocytes: carrier specificity and comparison with in vivo data. *J. Pharmacol. Exp. Ther.* 285:506–10
157. Brown GR. 1993. Cephalosporin-probenecid drug interactions. *Clin. Pharmacokinet.* 24:289–300
158. Marino EL, Dominguez-Gil A. 1981. The pharmacokinetics of cefadroxil associated with probenecid. *Int. J. Clin. Pharmacol. Ther. Toxicol.* 19:506–8
159. Griffith RS, Black HR, Brier GL, Wolny JD. 1977. Effect of probenecid on

- the blood levels and urinary excretion of cefamandole. *Antimicrob. Agents Chemother.* 11:809–12
160. Stoeckel K, Trueb V, Dubach UC, McNamara PJ. 1988. Effect of probenecid on the elimination and protein binding of ceftriaxone. *Eur. J. Clin. Pharmacol.* 34:151–56
161. Furst DE. 1995. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. *Br. J. Rheumatol.* 34(Suppl. 2):20–25
162. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, et al. 1992. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. *Eur. J. Clin. Pharmacol.* 42:121–25
163. Kremer JM, Hamilton RA. 1995. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. *J. Rheumatol.* 22:2072–77
164. Frenia ML, Long KS. 1992. Methotrexate and nonsteroidal antiinflammatory drug interactions. *Ann. Pharmacother.* 26:234–37
165. Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. 2004. Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. *J. Pharmacol. Exp. Ther.* 309:226–34
166. Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, et al. 1999. Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in *Xenopus laevis* oocytes. *Mol. Pharmacol.* 55:847–54
167. Uwai Y, Saito H, Inui K. 2000. Interaction between methotrexate and nonsteroidal anti-inflammatory drugs in organic anion transporter. *Eur. J. Pharmacol.* 409:31–36
168. Lu R, Chan BS, Schuster VL. 1999. Cloning of the human kidney PAH transporter: narrow substrate specificity and regulation by protein kinase C. *Am. J. Physiol. Renal Physiol.* 276:F295–303
169. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, et al. 2002. Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. *J. Neurochem.* 83:57–66
170. Sekine T, Cha SH, Tsuda M, Apiwattanakul N, Nakajima N, et al. 1998. Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. *FEBS Lett.* 429:179–82
171. Morita N, Kusuhara H, Sekine T, Endou H, Sugiyama Y. 2001. Functional characterization of rat organic anion transporter 2 in LLC-PK1 cells. *J. Pharmacol. Exp. Ther.* 298:1179–84
172. Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, et al. 1999. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. *J. Biol. Chem.* 274:13675–80
173. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, et al. 1999. The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. *J. Pharmacol. Exp. Ther.* 290:672–77
174. Takeda M, Babu E, Narikawa S, Endou H. 2002. Interaction of human organic anion transporters with various cephalosporin antibiotics. *Eur. J. Pharmacol.* 438:137–42
175. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, et al. 2002. Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. *Life Sci.* 70:1861–74
176. Uwai Y, Saito H, Inui K. 2002. Rat renal organic anion transporter rOAT1 mediated transport of urinary-excreted

- cephalosporins, but not of biliary excreted cefoperazone. *Drug Metab. Pharmacokin.* 17:125–29
177. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, et al. 2002. Role of human organic anion transporter 4 in the transport of ochratoxin A. *Biochim. Biophys. Acta* 1590:64–75
 178. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, et al. 2002. Human organic anion transporters mediate the transport of tetracycline. *Jpn. J. Pharmacol.* 88:69–76
 179. Uwai Y, Saito H, Hashimoto Y, Inui K. 2000. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. *J. Pharmacol. Exp. Ther.* 295:261–65
 180. Uwai Y, Saito H, Hashimoto Y, Inui K. 2000. Inhibitory effect of anti-diabetic agents on rat organic anion transporter rOAT1. *Eur. J. Pharmacol.* 398:193–97
 181. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. 2002. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. *Mol. Pharmacol.* 61:982–88
 182. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, et al. 2001. Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. *Eur. J. Pharmacol.* 419:113–20
 183. Enomoto A, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, et al. 2002. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. *J. Pharmacol. Exp. Ther.* 301:797–802
 184. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. 1999. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. *Drug Metab. Dispos.* 27:866–71
 185. Tokui T, Nakai D, Nakagomi R, Yawo H, Abe T, et al. 1999. Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. *Pharm. Res.* 16:904–8
 186. Kullak-Ublick GA, Fisch T, Oswald M, Hagenbuch B, Meier PJ, et al. 1998. Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain. *FEBS Lett.* 424:173–76
 187. Bossuyt X, Muller M, Hagenbuch B, Meier PJ. 1996. Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. *J. Pharmacol. Exp. Ther.* 276:891–96
 188. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, et al. 2001. Characterization of the efflux transport of 17 β -estradiol-D-glucuronide from the brain across the blood-brain barrier. *J. Pharmacol. Exp. Ther.* 298:316–22
 189. Sugiyama D, Kusuhara H, Shitara Y, Abe T, Sugiyama Y. 2002. Effect of 17 β -estradiol-D-17 β -glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates. *Drug Metab. Dispos.* 30:220–23
 190. Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, et al. 2001. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. *Gastroenterology* 120:1689–99
 191. Vavricka SR, van Montfoort J, Ha HR, Meier PJ, Fattinger K. 2002. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. *Hepatology* 36:164–72
 192. Fattinger K, Cattori V, Hagenbuch B, Meier PJ, Stieger B. 2000. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. *Hepatology* 32:82–86
 193. Ichimaru N, Takahara S, Kokado Y, Wang J-D, Hatori M, et al. 2001. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. *Atherosclerosis* 158:417–23

194. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. 1993. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. *Nephron* 65:410–13
195. Goldberg R, Roth D. 1996. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. *Transplantation* 62:1559–64
196. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Latila J, et al. 2001. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. *Clin. Pharmacol. Ther.* 69:340–45
197. Backman JT, Kyrklund C, Kivistö KT, Wang J-S, Neuvonen PJ. 2000. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. *Clin. Pharmacol. Ther.* 68:122–29
198. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. *Clin. Pharmacol. Ther.* 73:538–44
199. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. 1995. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. *Am. J. Cardiol.* 76: 80A–83
200. Mathew P, Cuddy T, Tracewell WG, Salazar D. 2004. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. *Clin. Pharmacol. Ther.* 75:P33

CONTENTS

FRONTISPIECE— <i>Minor J. Coon</i>	xii
CYTOCHROME P450: NATURE'S MOST VERSATILE BIOLOGICAL CATALYST, <i>Minor J. Coon</i>	1
CYTOCHROME P450 ACTIVATION OF ARYLAMINES AND HETEROCYCLIC AMINES, <i>Donghak Kim and F. Peter Guengerich</i>	27
GLUTATHIONE TRANSFERASES, <i>John D. Hayes, Jack U. Flanagan, and Ian R. Jowsey</i>	51
PLEIOTROPIC EFFECTS OF STATINS, <i>James K. Liao and Ulrich Laufs</i>	89
FAT CELLS: AFFERENT AND EFFERENT MESSAGES DEFINE NEW APPROACHES TO TREAT OBESITY, <i>Max Lafontan</i>	119
FORMATION AND TOXICITY OF ANESTHETIC DEGRADATION PRODUCTS, <i>M. W. Anders</i>	147
THE ROLE OF METABOLIC ACTIVATION IN DRUG-INDUCED HEPATOTOXICITY, <i>B. Kevin Park, Neil R. Kitteringham, James L. Maggs, Munir Pirmohamed, and Dominic P. Williams</i>	177
NATURAL HEALTH PRODUCTS AND DRUG DISPOSITION, <i>Brian C. Foster, J. Thor Arnason, and Colin J. Briggs</i>	203
BIOMARKERS IN PSYCHOTROPIC DRUG DEVELOPMENT: INTEGRATION OF DATA ACROSS MULTIPLE DOMAINS, <i>Peter R. Bieck and William Z. Potter</i>	227
NEONICOTINOID INSECTICIDE TOXICOLOGY: MECHANISMS OF SELECTIVE ACTION, <i>Motohiro Tomizawa and John E. Casida</i>	247
GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE, APOPTOSIS, AND NEURODEGENERATIVE DISEASES, <i>De-Maw Chuang, Christopher Hough, and Vladimir V. Senatorov</i>	269
NON-MICHAELIS-MENTEN KINETICS IN CYTOCHROME P450-CATALYZED REACTIONS, <i>William M. Atkins</i>	291
EPOXIDE HYDROLASES: MECHANISMS, INHIBITOR DESIGNS, AND BIOLOGICAL ROLES, <i>Christophe Morisseau and Bruce D. Hammock</i>	311

NITROXYL (HNO): CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY, <i>Jon M. Fukuto, Christopher H. Switzer, Katrina M. Miranda, and David A. Wink</i>	335
TYROSINE KINASE INHIBITORS AND THE DAWN OF MOLECULAR CANCER THERAPEUTICS, <i>Raoul Tibes, Jonathan Trent, and Razelle Kurzrock</i>	357
ACTIONS OF ADENOSINE AT ITS RECEPTORS IN THE CNS: INSIGHTS FROM KNOCKOUTS AND DRUGS, <i>Bertil B. Fredholm, Jiang-Fan Chen, Susan A. Masino, and Jean-Marie Vaugeois</i>	385
REGULATION AND INHIBITION OF ARACHIDONIC ACID (OMEGA)-HYDROXYLASES AND 20-HETE FORMATION, <i>Deanna L. Kroetz and Fengyun Xu</i>	413
CYTOCHROME P450 UBIQUITINATION: BRANDING FOR THE PROTEOLYTIC SLAUGHTER? <i>Maria Almira Correia, Sheila Sadeghi, and Eduardo Mundo-Paredes</i>	439
PROTEASOME INHIBITION IN MULTIPLE MYELOMA: THERAPEUTIC IMPLICATION, <i>Dharminder Chauhan, Teru Hideshima, and Kenneth C. Anderson</i>	465
CLINICAL AND TOXICOLOGICAL RELEVANCE OF CYP2C9: DRUG-DRUG INTERACTIONS AND PHARMACOGENETICS, <i>Allan E. Rettie and Jeffrey P. Jones</i>	477
CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS, <i>Daryl C. Drummond, Charles O. Noble, Dmitri B. Kirpotin, Zexiong Guo, Gary K. Scott, and Christopher C. Benz</i>	495
THE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS, <i>Ying Zhang</i>	529
MOLECULAR MECHANISMS OF RESISTANCE IN ANTIMALARIAL CHEMOTHERAPY: THE UNMET CHALLENGE, <i>Ravit Arav-Boger and Theresa A. Shapiro</i>	565
SIGNALING NETWORKS IN LIVING CELLS, <i>Michael A. White and Richard G.W. Anderson</i>	587
HEPATIC FIBROSIS: MOLECULAR MECHANISMS AND DRUG TARGETS, <i>Sophie Lotersztajn, Boris Julien, Fatima Teixeira-Clerc, Pascale Grenard, and Ariane Mallat</i>	605
ABERRANT DNA METHYLATION AS A CANCER-INDUCING MECHANISM, <i>Manel Esteller</i>	629
THE CARDIAC FIBROBLAST: THERAPEUTIC TARGET IN MYOCARDIAL REMODELING AND FAILURE, <i>R. Dale Brown, S. Kelley Ambler, M. Darren Mitchell, and Carlin S. Long</i>	657

EVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS, <i>Yoshihisa Shitara, Hitoshi Sato, and Yuichi Sugiyama</i>	689
DUAL SPECIFICITY PROTEIN PHOSPHATASES: THERAPEUTIC TARGETS FOR CANCER AND ALZHEIMER'S DISEASE, <i>Alexander P. Ducruet, Andreas Vogt, Peter Wipf, and John S. Lazo</i>	725
INDEXES	
Subject Index	751
Cumulative Index of Contributing Authors, Volumes 41–45	773
Cumulative Index of Chapter Titles, Volumes 41–45	776
ERRATA	
An online log of corrections to <i>Annual Review of Pharmacology and Toxicology</i> chapters may be found at http://pharmtox.annualreviews.org/errata.shtml	